Insmed Incorporated (NASDAQ:INSM) Overview

Company Overview - Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focused on developing therapies for rare diseases, known for its innovative approach to addressing unmet medical needs [1] - Competitors include other biotech firms specializing in rare diseases, such as Vertex Pharmaceuticals and BioMarin Pharmaceutical [1] Financial Performance - On February 19, 2026, Stifel Nicolaus set a price target of $205 for INSM, indicating a potential upside of 28.22% from the stock's price of $159.88 at that time, reflecting a strategic reassessment from a previous target of $212 [2] - The stock is currently trading at $161, showing a 6.54% increase with a recent price change of $9.89 [2] - Insmed's Q4 2025 earnings call provided insights into the company's financial health and strategic plans, covering key financial metrics such as revenue and profit margins [3] Stock Performance - The stock has shown significant volatility, with a daily range between $147.26 and $163.14 [4] - Over the past year, INSM has reached a high of $212.75 and a low of $60.40, indicating substantial price fluctuations [4] - The company's market capitalization is approximately $34.34 billion, with a trading volume of 4,921,823 shares, reflecting active investor interest [4]